(Q37501587)

20 August 2017

1 reference

title

Liver transplantation for hepatitis B virus. Pre-emptive and peri-operative prophylaxis (English)

1 reference

20 August 2017

main subject

liver transplantation

1 reference

1 reference

1 reference

A Mas

1

1 reference

20 August 2017

publication date

1 May 2009

1 reference

Digestive and Liver Disease

20 August 2017

published in

1 reference

20 August 2017

volume

41 Suppl 2

1 reference

20 August 2017

page(s)

S191-4

1 reference

Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2809%2960443-6

7 January 2021

Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2809%2960443-6

7 January 2021

Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2809%2960443-6

7 January 2021

Liver transplantation for patients with lamivudine-resistant HBV: what is the optimal prophylactic strategy?

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2809%2960443-6

7 January 2021

Liver transplantation in European patients with the hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2809%2960443-6

7 January 2021

Prophylaxis with anti-HBs immune globulins and nucleoside analogues after liver transplantation for HBV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2809%2960443-6

7 January 2021

Reduced doses of hepatitis B immunoglobulin protect against hepatitis B virus infection recurrence after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2809%2960443-6

7 January 2021

HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2809%2960443-6

7 January 2021

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2809%2960443-6

7 January 2021

Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2809%2960443-6

7 January 2021

Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2809%2960443-6

7 January 2021

Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2809%2960443-6

7 January 2021

Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2809%2960443-6

7 January 2021

Adefovir dipivoxil for wait-listed and post–liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2809%2960443-6

7 January 2021

Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2809%2960443-6

7 January 2021

Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2809%2960443-6

7 January 2021

Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2809%2960443-6

7 January 2021

A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2809%2960443-6

7 January 2021

Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2809%2960443-6

7 January 2021

10.1016/S1590-8658(09)60443-6

Identifiers

DOI

1 reference

20 August 2017

1 reference